Received: 21 June 2022 | Revised: 16 September 2022 | Accepted: 26 September 2022

DOI: 10.1002/ccr3.6444

CASE REPORT

Clinical Case Reports Open Access WILEY

Successful desensitization after hypersensitivity reaction to cisplatin in a patient with nasopharyngeal carcinoma

Arisa Kinouchi | **Hiroki Ishii** | **Kaname Sakamoto** | **Daiju Sakurai**

Department of Otolaryngology, Head and Neck Surgery, Interdisciplinary Graduate School of Medical Science, University of Yamanashi, Chuo, Japan

Correspondence
Hiroki Ishii, Department of Otolaryngology, Head and Neck Surgery, Interdisciplinary Graduate School of Medical Science, University of Yamanashi, 1110, Shimokato, Chuo-city, Yamanashi 409-3898, Japan.
Email: ishiih@yamanashi.ac.jp

Abstract

Hypersensitivity reaction to cisplatin can result in discontinuation of chemoradiotherapy in patients with head and neck squamous cell carcinoma. We describe a patient with nasopharyngeal carcinoma who developed cisplatin hypersensitivity and was successfully treated with cisplatin desensitization. Furthermore, it had little impact on the therapeutic performance of cisplatin-combined chemoradiotherapy.

KEYWORDS

carboplatin, cisplatin, desensitization, hypersensitivity reaction, nasopharyngeal carcinoma

1 | INTRODUCTION

Cisplatin (CDDP) is a platinum-based chemotherapeutic agent. It is the backbone of cancer treatment for various types of cancers, and credible evidence indicates that it is effective for head and neck squamous cell carcinoma (HNSCC). However, repeated exposure to platins, such as CDDP and carboplatin (CBDCA), increases the risk of hypersensitivity reaction (HSR) to platins.[1] HSR to platins critically influences the patient's prognosis. Desensitization therapy has been proposed for patients with gynecological cancer who are at risk of HSR.[2] Although several studies have evaluated the effectiveness and safety of desensitization with platins, few reports have described desensitization to CDDP in patients with HNSCC.

We herein present a case of acceptable re-challenge in a patient with nasopharyngeal cancer who had a history of HSR to CBDCA. The patient underwent a desensitization protocol for HSR to CDDP involving a series of CDDP administrations diluted by 10 times the desired dose. Although a mild urticarial rash occurred during CDDP desensitization therapy, the patient tolerated a cumulative dose of 200 mg/m^2, and no recurrence was detected 1 year after chemoradiotherapy with desensitization.

2 | CASE PRESENTATION

A 75-year-old Japanese woman presented for evaluation of bilateral neck swelling. She had a medical history of uterine cancer treated by total hysterectomy with bilateral salpingo-oophorectomy and pelvic lymph node dissection at 58 years of age, followed by six cycles of adjuvant chemotherapy with CBDCA (area under the blood drug concentration–time curve of 6 mg×h/L) and paclitaxel (180 mg/m^2). Computed tomography and magnetic resonance imaging revealed a neoplastic process in the right fossa of Rosenmüller with invasion of the parapharyngeal space and bilateral enlarged upper-middle internal jugular lymph nodes with necrosis; however, there was no evidence of distant metastatic disease (Figure 1). Pathological examination revealed a non-keratinizing nasopharyngeal carcinoma. The patient was clinically diagnosed with advanced nasopharyngeal carcinoma (cT2N3M0, Stage



FIGURE 1 Computed tomography images before chemoradiotherapy. (A) An enhancing soft tissue lesion was located in the right wall of the nasopharynx (red arrow). Gadolinium-enhanced T1-weighted magnetic resonance imaging showed, (B) invasion of the tumor into the parapharyngeal space, and (C) multiple enlarged lymph nodes with necrosis in the bilateral upper-middle neck. The arrow indicates the tumor area.



FIGURE 2 Timeline and duration of the CDDP desensitization treatment

IVA). She started chemoradiotherapy using CDDP, which is a scheduled intensity-modulated radiotherapy (70 Gy in 35 fractions), with three cycles of concomitant CDDP (100 mg/m^2) once every 3 weeks. Although no adverse effects occurred during the first cycle of CDDP, the patient developed a feeling of malaise 16 min after the start of the second CDDP administration on day 22. She then further developed urticaria on her neck with itching, followed by vomiting, cold skin, and bowel incontinence. Her blood pressure temporarily decreased to 67/43 mmHg, and her oxygen saturation decreased to 93% on room air. Because these observations suggested a state of shock, a clinical diagnosis of CDDP anaphylaxis was made. The infusion was immediately stopped, and first-line treatments were administered (intramuscular adrenaline, high-flow oxygen, and saline infusion). Intravenous hydrocortisone and chlorophenylamine were also given. The patient appeared to recover, and no additional interventions were needed. Approximately 20 mg of CDDP had been administered during the infusion.

HSR to CDDP was strongly suspected. Because there were no alternative treatments as effective as the current treatment using CDDP to control the targeted lesions, CDDP desensitization therapy was performed with the approval of our institution's ethics committee. This desensitization protocol involved four different solutions of 1/1000-, 1/100-, and 1/10-diluted CDDP as well as the original concentration. First, 500 ml of normal saline containing the target dose (140 mg) of CDDP was processed as the original solution. Next, this original concentration was diluted 10 (solution #3), 100 (solution #2), or 1000 times (solution #1) by saline. After the patient had been premedicated with an H1 antagonist (chlorpheniramine), H2 antagonist (famotidine, 20 mg), and glucocorticoid (dexamethasone, 6.6 mg), these processed solutions were administered in the order of lowest to highest CDDP concentration.

Desensitization therapy started 14 days after the development of HSR to CDDP. The timeline of desensitization is shown in Figure 2. The infusion of solutions #1 and #2 was smoothly completed with no allergic reactions indicating hypersensitivity to CDDP. However, after the scheduled administration of solution #3 at a 1 h interval, grade 1 redness and itching of about 30 mm in diameter appeared

at the injection site. To allow for continuation of the desensitization with the original solution, clobetasol propionate ointment 0.05% was applied to the injection site. Although the infusion rate of the original solution was decreased from 160 to 120 ml/h, grade 1 urticaria broadly spread to the patient's face and neck with dry coughing 1 h after starting desensitization (Figure 3). We reduced the infusion rate to 90 ml/h in a stepwise manner; however, the urticaria continued spreading to her abdomen and lower legs 2.5 h after the start of desensitization with solution #4 (grade 2). She was administered 100 mg of hydrocortisone, and all symptoms resolved within 30 min. Finally, a target dose of CDDP was administered successfully with no further reactions.

The patient completed radiotherapy (total dose of 70 Gy in 35 fractions) and was discharged 2 weeks after the scheduled CDDP desensitization therapy. Computed tomography revealed significant therapeutic responses at both the primary site and bilateral neck lymph nodes at 3 months postdesensitization (Figure 4). A complete response was achieved. At the time of this writing, the patient had been alive and well without disease for 1 year.

3 | DISCUSSION

CDDP commonly causes emesis, myelotoxicity, nephrotoxicity, and ototoxicity.[3] Incidentally, some patients develop HSR to CDDP.[4] The mechanism of HSR to platins is unclear but is considered to be an immune reaction that occurs via immunoglobulin E-mediated activation of mast cells and their rapid degranulation with the release of histamine.[5]



FIGURE 3 Clinical photographs demonstrating hypersensitivity reactions during CDDP desensitization. (A) Pruritus appeared around the injection area. (B) Redness on the face.

Symptoms of mild HSR include skin rash, urticaria, flushing, palmar itching, burning, edema of the face and hands, abdominal cramping and diarrhea, back pain, and pruritus. Severe HSR can be life-threatening if the patient develops severe hypotension, bronchospasm, cardiac dysfunction, or anaphylaxis.[6] A recent review indicated that because HSR to platins is uncommon, current studies cannot identify consistent risk factors with an adequately high level of evidence.[5] Repeated exposure to platins directly increases the risk of HSR, and HSR often occurs after the administration of multiple cycles.[7] In patients receiving CBDCA, a platinum-free interval of >12 months and a cumulative dose of >650 mg are associated with the incidence of HSR.[8,9] The frequency of HSR to CDDP ranges from 5% to 20% and increases with concomitant radiation therapy in patients with gynecologic cancers, but the incidence of HSR in patients with head and neck cancers is unknown because it rarely occurs.[10] In this case, the patient had received a cumulative CBDCA dose of 3900 mg, and her sensitization to platins may have progressed over time. This may be explained by the cross-reactivity among platinum agents. The cross-reactivity between CDDP and CBDCA can be explained by the similarity of their structure. The central core of all platins is a platinum atom coordinated with two nitrogens. The structure of two primary amine chains (NH_3), which are shared by CBDCA and CDDP, could be due to the cross-reactivity between these two drugs.[11] Thus, our patient may have developed HSR to CDDP after multiple exposures to CBDCA. Because there is little evidence of HSR to platins in patients with head and neck cancers, we were unable to anticipate the risk of HSR before initiation of our patient's treatment. Before administering platinum-based chemotherapy, skin testing can be performed to evaluate the risk of HSR in patients with a history of platinum administration.[12] Pradelli et al.[13] reported that the negative predictive value for skin testing was 92% for all platins, 100% for CDDP, and 87% for CBDCA. However, we were unable to perform skin testing or blood examination of cisplatin-specific IgE before CDDP desensitization therapy because it was not covered by insurance in Japan. Skin testing to evaluate the risk of HSR to platinum agents is also considered unethical because of adverse events such as irritant reactions and is therefore not routinely conducted.[11]

Several desensitization protocols for CDDP or CBDCA in patients with gynecologic cancer have been described. Many previously reported protocols involve 12 steps using 3 dilutions (1:100, 1:10, and 1:1) by increasing the infusion rate; however, such protocols are



FIGURE 4 Computed tomography images 3 months after chemoradiotherapy. The Images showed disappearance of (A) the enhancing lesions in the right nasopharynx and (B) multiple enlarged bilateral cervical lymph nodes.

complicated.[10] Therefore, with reference to a previous report by Takase et al.,[14] we performed a desensitization protocol with four different solutions (1/1000-, 1/100-, and 1/10-diluted CDDP as well as undiluted CDDP). We adopted this protocol because of its simplicity and rapidity. Takase et al.[14] reported that the completion rate of this protocol was 95.2% in a group of 20 patients, among whom only 1 developed grade 3 HSR. Their result encouraged us to use this protocol with effectiveness and safety.

4 | CONCLUSION

We have reported a case of successful desensitization therapy in a patient with HNSCC who developed HSR to CDDP. At the time of this writing, CDDP-combined radiotherapy with the herein-described desensitization protocol had maintained long-term remission of nasopharyngeal cancer for more than 1 year. Although HSR to platins rarely occurs in patients with HNSCC, it can occur whenever there is re-exposure to platins. Furthermore, a CDDP desensitization protocol using a series of CDDP administrations diluted by 10 times the desired dose was clinically acceptable and safe. However, because of the limited number of reports of HSR to platins in patients with HNSCC, the findings in the present case will encourage medical colleagues working in the field of head and neck surgery worldwide to use this protocol of desensitization to CDDP in their clinical practice. Further studies are warranted to overcome platinum hypersensitivity and safely administer desensitization protocols to these patients.

AUTHOR CONTRIBUTIONS

The authors confirm their contributions to the manuscript as follows. Study conception and design: A. Kinouchi and D. Sakurai. Clinical data collection: A. Kinouchi and K. Sakamoto. Drafting and editing of the manuscript: A. Kinouchi and H. Ishii. All the authors approved the final version of the manuscript.

ACKNOWLEDGMENTS

All the authors thank the patient for allowing publication of this case study. The authors also thank Angela Morben, DVM, ELS, from Edanz, for editing a draft of this manuscript.

CONFLICT OF INTEREST

The authors declare no conflicts of interests.

DATA AVAILABILITY STATEMENT

All the required information is available in the manuscript.

ETHICAL APPROVAL

This study protocol was approved by the ethics committee of Yamanashi University Faculty of Medicine.

CONSENT

Written informed consent was obtained from the patient for publication of this case report and accompanying images in accordance with the journal's patient consent policy.

ORCID

Hiroki Ishii https://orcid.org/0000-0003-1329-2180

REFERENCES

1. Otani IM, Wong J, Banerji A. Platinum chemotherapy hypersensitivity: prevalence and management. *Immunol Allergy Clin North Am*. 2017;37:663-677.
2. Vetter MH, Castaneda A, Khan A, O'Malley DM. A clinical classification system for grading platinum hypersensitivity reactions. *Gynecol Oncol*. 2020;159:794-798.

3. Karasawa T, Steyger PS. An integrated view of cisplatin-induced nephrotoxicity and ototoxicity. *Toxicol Lett*. 2015;237:219-227.
4. Caiado J, Castells M. Presentation and diagnosis of hypersensitivity to platinum drugs. *Curr Allergy Asthma Rep*. 2015;15:15.
5. Miyamoto S, Okada R, Ando K. Platinum hypersensitivity and desensitization. *Jpn J Clin Oncol*. 2015;45:795-804.
6. Makrilia N, Syrigou E, Kaklamanos I, Manolopoulos L, Saif MW. Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. *Met Based Drugs*. 2010;2010:207084.
7. Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. *Oncologist*. 2007;12:601-609.
8. Schwartz JR, Bandera C, Bradley A, et al. Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from women and Infants' Hospital. *Gynecol Oncol*. 2007;105:81-83.
9. Sugimoto H, Iwamoto T, Murashima Y, Tabata T, Sagawa N, Okuda M. Risk factors contributing to the development of carboplatin-related delayed hypersensitivity reactions in Japanese patients with gynecologic cancers. *Cancer Chemother Pharmacol*. 2011;67:415-419.
10. Tsao LR, Young FD, Otani IM, Castells MC. Hypersensitivity reactions to platinum agents and taxanes. *Clin Rev Allergy Immunol*. 2022;62(3):432-448.
11. Caiado J, Venemalm L, Pereira-Santos MC, Costa L, Barbosa MP, Castells M. Carboplatin-, oxaliplatin-, and cisplatin-specific IgE: cross-reactivity and value in the diagnosis of carboplatin and oxaliplatin allergy. *J Allergy Clin Immunol Pract*. 2013;1:494-500.
12. Caiado J, Picard M. Diagnostic tools for hypersensitivity to platinum drugs and taxanes: skin testing, specific IgE, and mast cell/basophil mediators. *Curr Allergy Asthma Rep*. 2014;14:451.
13. Pradelli J, Verdoire P, Boutros J, et al. Allergy evaluation of hypersensitivity to platinum salts and taxanes: a six-year experience. *J Allergy Clin Immunol Pract*. 2020;8:1658-1664.
14. Takase N, Matsumoto K, Onoe T, et al. 4-step 4-h carboplatin desensitization protocol for patients with gynecological malignancies showing platinum hypersensitivity: a retrospective study. *Int J Clin Oncol*. 2015;20:566-573.

How to cite this article: Kinouchi A, Ishii H, Sakamoto K, Sakurai D. Successful desensitization after hypersensitivity reaction to cisplatin in a patient with nasopharyngeal carcinoma. *Clin Case Rep*. 2022;10:e06444. doi: 10.1002/ccr3.6444